Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer
定量模型预测下一代抗 NKG2A 单克隆抗体在癌症治疗方面较莫那珠单抗的竞争优势
期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3.1
doi:10.1002/psp4.12592
Phillip Spinosa, Monika Musial-Siwek, Marc Presler, Alison Betts, Emily Rosentrater, Janice Villali, Lucia Wille, Yang Zhao, Tom McCaughtry, Kalyanasundaram Subramanian, Hanlan Liu
